Additionally, it has been documented in the literature that TRF2 is crucial to the pathological development of prostate tumors and that prostate tumors with low levels of TRF2 expression are categorized as high-grade androgen receptor-negative tumors 85, 90. This evidence concerns the gene TERF2 and prostate neoplasm.